6
Oct
2026

Coripharma

Exhibitor at CPHI Milan 2026 stand 18D55, Finished Dosage & Formulation
About Us

Coripharma is an established European generic pharmaceutical company with a powerful heritage. 

We offer out-licensing of our own developed products as well as contract manufacturing to generic pharmaceutical companies demanding high quality services from a reliable European partner.

Coripharma was founded in 2018, but our dynamic team draws from decades of knowledge and experience in the pharmaceutical industry. Our manufacturing site is located on Iceland’s southern peninsula and has been a pillar in our ...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Iceland
  • On CPHI since:
    2020
  • Employees:
    100 - 249
Company types
Pharmaceutical company
View company profile
Contact info
  • 7729606
  • Website
  • Reykjavikurvegur 78 - 80, 220, Hafnarfjordur, Iceland
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 18D55, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Ivacaftor

    Product Ivacaftor

    Ivacaftor is used for the treatment of Cystic Fibrosis (CF) which is an inherited life-threatening disease. Ivacaftor FC tablets come in two strengths, 75 mg and 150 mg, that can either be used as a monotherapy, or in combination with either tezacaftor or both tezacaftor and elexacaftor. Pivotal BE studies...
  • Coripharma Dossier List

    Product Coripharma Dossier List

    We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 30 own developed dossiers either in our pipeline or already available. C...
  • Ponatinib

    Product Ponatinib

    Ponatinib FC tablets come in three strengths, 15 mg, 30 mg and 45 mg and are used to treat Leukemia. Pivotal BE study is completed and passing and the dossier will be available in Q1 2026. DCP slot requested in May 2026. 

    Coripharma`s generic version of Ponatinib is being developed in our R&...
  • Enzalutamide

    Product Enzalutamide

    Enzalutamide is used for the treatment of Prostate Cancer. Enzalutamide FC tablets come in three strengths, 40 mg, 80 mg and 160 mg, where the recommended dose is 160 mg as a single daily dose.
    Coripharma`s generic version of Enzalutamide is being developed in our R&D facility located in Iceland, wh...
  • Binimetinib

    Product Binimetinib

    Binimetinib FC tablets come in two strengths, 15 mg and 45 mg, and are used in combination with Encorafenib for the treatment of Melanoma. Pivotal BE studies for Binimetinib are planned in Q4 2025 and the dossier will be available in Q2 2026. DCP slot requested in September 2026.

    Coripharma`s g...